All In Biotech

Drug Trial Radar · NCT05850234

AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)

A Phase Ib/II Study of AZD0120, Dual-Targeting Autologous Chimeric Antigen Receptor T-cell (CAR T) Therapy Directed Against CD19 and B-cell Maturation Antigen (BCMA) in Participants With Relapsed/Refractory Multiple Myeloma (DURGA-1)

Last checked: Nov 19, 2026Latest source record: Oct 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

232

Planned (sponsor's estimate)

Start

Jul 20, 2023

Primary completion

Oct 1, 2027

Study completion Jan 25, 2029

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
First posted
May 9, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This trial is a Phase 1b/2, open-label, multicenter study of AZD0120, a CD19/BCMA dual CAR T-cell therapy, in adult subjects with relapsed/refractory multiple myeloma.

Conditions

  • Relapsed/Refractory Multiple Myeloma

Interventions

  • AZD0120Biological

    AZD0120 is a BCMA/CD19 dual CAR T product under investigation for the treatment of participants with RRMM.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase 1b: Adverse Events (AEs)Time frame: Through study completion, a minimum of 2 years.
  2. Phase 1b: Dose-Limiting Toxicities (DLTs)Time frame: 28 days
  3. Phase 2: Objective Response Rate (ORR)Time frame: Through study completion, a minimum of 2 years.

Locations

36 sites in 1 country. Site status is shown where the registry gives one.

  • Research Site

    Birmingham, Alabama · Recruiting

  • Research Site

    Phoenix, Arizona · Recruiting

  • Research Site

    La Jolla, California · Recruiting

  • Research Site

    Los Angeles, California · Recruiting

  • Research Site

    San Francisco, California · Recruiting

  • Research Site

    Aurora, Colorado · Recruiting

  • Research Site

    Denver, Colorado · Recruiting

  • Research Site

    Jacksonville, Florida · Recruiting

  • Research Site

    Miami, Florida · Recruiting

  • Research Site

    Tampa, Florida · Recruiting

  • Research Site

    Atlanta, Georgia · Recruiting

  • Research Site

    Chicago, Illinois · Recruiting

  • Research Site

    Iowa City, Iowa · Recruiting

  • Research Site

    Boston, Massachusetts · Recruiting

  • Research Site

    Boston, Massachusetts · Recruiting

  • Research Site

    Ann Arbor, Michigan · Recruiting

  • Research Site

    Detroit, Michigan · Recruiting

  • Research Site

    Minneapolis, Minnesota · Recruiting

  • Research Site

    Rochester, Minnesota · Recruiting

  • Research Site

    Omaha, Nebraska · Withdrawn

  • Research Site

    Hackensack, New Jersey · Withdrawn

  • Research Site

    Buffalo, New York · Withdrawn

  • Research Site

    New York, New York · Recruiting

  • Research Site

    Stony Brook, New York · Recruiting

  • Research Site

    Charlotte, North Carolina · Recruiting

  • Research Site

    Durham, North Carolina · Recruiting

  • Research Site

    Nashville, Tennessee · Recruiting

  • Research Site

    Nashville, Tennessee · Recruiting

  • Research Site

    Austin, Texas · Recruiting

  • Research Site

    Dallas, Texas · Recruiting

  • Research Site

    Houston, Texas · Recruiting

  • Research Site

    Salt Lake City, Utah · Recruiting

  • Research Site

    Charlottesville, Virginia · Recruiting

  • Research Site

    Edmonds, Washington · Recruiting

  • Research Site

    Seattle, Washington · Recruiting

  • Research Site

    Milwaukee, Wisconsin · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.